Table 2.

Main treatments currently employed for MEN1 pNETs.

Surgery

Pharmacological therapies Biotherapies Long-lasting somatostatin analogues (octreotide and lanreotide) Inhibitors of mammalian target of rapamycin (everolimus) Inhibitors of tyrosine kinase receptors (sunitinib) Chemotherapies Alkylating agents (streptozocin, temozolomide, and cisplatin) Anti-microtubule agents (etoposide and docetaxel) Topoisomerase inhibitors (doxorubicin and irinotecan) Antimetabolites (5fluorouracil, capecitabine and gemcitabine) Cytotoxic antibiotics (actinomycin D, mitomycin C, doxorubicin and mixoxantrone) Combination of more than one chemotherapy compound

Tumor targeted radiotherapy Peptide receptor radionuclide therapy with somatostatin analogues (octreotide, octreotate, dototate, or dotatoc) bound to 90Yttrium or 177Lutetium